首页 News 正文

12 weeks of weight loss exceeding 13%. Novo Nordisk's oral therapy has been declared clinically in China

dinghong
3189 0 0

The oral therapy of Novo Nordisk with a weight loss of over 13% in 12 weeks has been applied for clinical trials in China. According to the official website of the Drug Evaluation Center (CDE) of the National Medical Products Administration of China, the clinical trial application for Novo Nordisk's Class 1 new drug, amycretin tablets, has been accepted. Public information shows that this is a long-acting co agonist developed by Novo Nordisk for oral GLP-1 receptor and amylin receptor, serving as a new generation of weight loss therapy.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

dinghong 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    0